XML 35 R24.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

SEGMENT INFORMATION (Tables) | 9 Months Ended
--- | ---
Jun. 30, 2024
SEGMENT INFORMATION |
Schedule of information regarding operations by segment | Information regarding operations by segment for the three-month period ended June 30, 2024 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  | ​
​ |  | Production |  | Services and Kits |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | 218,858 | ​ | $ | — | ​ | $ | 27,786 | ​ | $ | 246,644
Service revenues | ​ |  | 59,901 | ​ |  | — | ​ |  | 166,244 | ​ |  | 226,145
Clinical laboratory service revenues | ​ |  | — | ​ |  | 325,930 | ​ |  | — | ​ |  | 325,930
Less intersegment revenues | ​ |  | — | ​ |  | (1,200) | ​ |  | — | ​ |  | (1,200)
Total revenues | ​ | ​ | 278,759 | ​ | ​ | 324,730 | ​ | ​ | 194,030 | ​ | ​ | 797,519
Gross profit | ​ | ​ | 194,341 | ​ | ​ | (12,260) | ​ | ​ | 63,151 | ​ | ​ | 245,232
Loss from segment operations (a) | ​ | ​ | (1,319,093) | ​ | ​ | (231,160) | ​ | ​ | (693,953) | ​ | ​ | (2,244,206)
​ Information regarding operations by segment for the three-month period ended June 30, 2023 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  | ​
​ |  | Production |  | Services |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | 230,544 | ​ | $ | — | ​ | $ | 86,406 | ​ | $ | 316,950
Service revenues | ​ |  | 174,962 | ​ |  | — | ​ |  | 250,732 | ​ |  | 425,694
Clinical laboratory service revenues | ​ |  | — | ​ |  | 2,188,817 | ​ |  | — | ​ |  | 2,188,817
Less intersegment revenues | ​ |  | — | ​ |  | (14,120) | ​ |  | — | ​ |  | (14,120)
Total revenues | ​ | $ | 405,506 | ​ | $ | 2,174,697 | ​ | $ | 337,138 | ​ | $ | 2,917,341
Gross profit | ​ | $ | 290,541 | ​ | $ | 829,798 | ​ | $ | 148,979 | ​ | $ | 1,269,318
(Loss) income from segment operations (a) | ​ | $ | (717,126) | ​ | $ | 14,742 | ​ | $ | (998,966) | ​ | $ | (1,701,350)
​ Information regarding operations by segment for the nine-month period ended June 30, 2024 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  | ​
​ |  | Production |  | Services and Kits |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | 477,010 | ​ | $ | — | ​ | $ | 470,076 | ​ | $ | 947,086
Service revenues | ​ |  | 202,635 | ​ |  | — | ​ |  | 476,142 | ​ |  | 678,777
Clinical laboratory service revenues | ​ |  | — | ​ |  | 1,004,250 | ​ |  | — | ​ |  | 1,004,250
Less intersegment revenues | ​ |  | — | ​ |  | (11,800) | ​ |  | — | ​ |  | (11,800)
Total revenues | ​ | $ | 679,645 | ​ | $ | 992,450 | ​ | $ | 946,218 | ​ | $ | 2,618,313
Gross profit | ​ | $ | 462,464 | ​ | $ | (56,703) | ​ | $ | 366,219 | ​ | $ | 771,980
Loss from segment operations (a) | ​ | $ | (3,743,588) | ​ | $ | (1,026,263) | ​ | $ | (1,978,308) | ​ | $ | (6,748,159)
Information regarding operations by segment for the nine-month period ended June 30, 2023 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  | ​
​ |  | Production |  | Services |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | 560,000 | ​ | $ | — | ​ | $ | 570,800 | ​ | $ | 1,130,800
Service revenues | ​ |  | 434,287 | ​ |  | — | ​ |  | 392,526 | ​ |  | 826,813
Clinical laboratory service revenues | ​ |  | — | ​ |  | 10,726,214 | ​ |  | — | ​ |  | 10,726,214
Less intersegment revenues | ​ |  | — | ​ |  | (96,120) | ​ |  | — | ​ |  | (96,120)
Total revenues | ​ | $ | 994,287 | ​ | $ | 10,630,094 | ​ | $ | 963,326 | ​ | $ | 12,587,707
Gross profit | ​ | $ | 676,942 | ​ | $ | 4,413,130 | ​ | $ | 364,364 | ​ | $ | 5,454,436
(Loss) income from segment operations (a) | ​ | $ | (2,623,502) | ​ | $ | 1,616,914 | ​ | $ | (2,388,417) | ​ | $ | (3,395,005)
| (a) | Segment operating (loss) income consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.
Schedule of reconciliation of segment loss from operations to corporate (loss) income | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30,
​ |  | 2024 |  | 2023
Loss from operations of reportable segments | ​ | $ | (2,244,206) | ​ | $ | (1,701,350)
General corporate expenses (b) | ​ |  | (1,102,487) | ​ |  | (1,157,759)
Interest income | ​ |  | 36,295 | ​ |  | 26,783
Unrealized gain (loss) on change in fair value of warrants classified as a liability | ​ | ​ | 5,160,000 | ​ | ​ | (278,400)
Other (expense) income, net | ​ | ​ | (101) | ​ | ​ | (3,469)
Consolidated income (loss) before provision for income taxes | ​ | $ | 1,849,501 | ​ | $ | (3,114,195)
​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30,
​ |  | 2024 |  | 2023
Loss from operations of reportable segments | ​ | $ | (6,748,159) | ​ | $ | (3,395,005)
General corporate expenses (b) | ​ |  | (4,005,351) | ​ |  | (3,387,464)
Interest income | ​ |  | 84,972 | ​ |  | 34,108
Unrealized gain on change in fair value of warrants classified as a liability | ​ |  | 9,564,000 | ​ |  | 334,700
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification | ​ | ​ | (394,000) | ​ | ​ | —
Transaction costs allocated to registered direct offering | ​ | ​ | (633,198) | ​ | ​ | —
Loss on issuance of warrants | ​ | ​ | (1,633,767) | ​ | ​ | —
Other (expense) income, net | ​ |  | (9,060) | ​ |  | 6,396
Consolidated loss before provision for income taxes | ​ | $ | (3,774,563) | ​ | $ | (6,407,265)
| (b) | General corporate expenses consist of selling, general and administrative expenses that are not specifically identifiable to a segment.

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration